Bevacizumab (Avastin) Could Play An Important Role In Improving The Neurocognitive Function Of Patients With The Most Aggressive Form Of Brain Cancer

Roche today announced that an analysis of the phase II BRAIN study of bevacizumab (Avastin®) alone or in combination with irinotecan chemotherapy for the treatment of relapsed or progressive glioblastoma (GBM) demonstrated that in addition to increasing the chance of patients being alive without